| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
PEGs
PROTAC Linkers. |
|---|---|
| ln Vitro |
One ligand is for an E3 ubiquitin ligase, and the other is for the target protein; these two ligands are joined by a linker to form PROTACs. The intracellular ubiquitin-proteasome system is utilized by PROTACs to specifically destroy target proteins[1].
As a linker molecule, this compound itself has no intrinsic biological activity; it serves as a structural connector that joins a target protein ligand and an E3 ubiquitin ligase ligand in PROTAC synthesis. Its chemical structure is designed to provide optimal distance and flexibility between the two protein-binding moieties to facilitate ternary complex formation. |
| ln Vivo |
No specific in vivo activity has been reported for this linker alone; its activity is derived from the final PROTAC molecule after conjugation with appropriate ligands. In vivo studies for the complete PROTAC are conducted in animal models to assess target degradation and therapeutic efficacy.
|
| Enzyme Assay |
N/A; this compound is not assessed in isolated enzyme/receptor binding assays. As a synthetic intermediate, its quality is confirmed by analytical methods such as HPLC, with a standard purity of 98%, and the structure is verified by NMR and mass spectrometry.
|
| Cell Assay |
N/A; this linker is not tested alone in cell-based assays. It is used as a building block for constructing PROTAC molecules for cellular degradation studies. In a typical procedure, the linker is first conjugated to an E3 ligase ligand, then to a target ligand, and the resulting PROTAC is tested in cells.
|
| Animal Protocol |
N/A; no animal studies are performed with the linker alone. For the complete PROTAC conjugate, animal studies are conducted following institutional guidelines. The test compound is typically formulated in a vehicle such as saline or PEG-based solutions and administered via oral gavage, IP, or IV injection.
|
| ADME/Pharmacokinetics |
The hydrochloride salt form enhances water solubility. The compound has a molecular weight of 260.20, a molecular formula of C10H23Cl2NO2, and is typically stored as a powder at -20degC for up to 3 years. It is soluble in DMSO at approximately 41.67 mg/mL (160.15 mM) and in water.
|
| Toxicity/Toxicokinetics |
This product is for research use only and is not intended for human or veterinary use. Standard safety practices for handling chemical reagents should be followed. Avoid moisture and exposure to light during storage.
|
| References | |
| Additional Infomation |
The terminal amine group can be used to form an amide bond with a carboxylic acid-containing target protein ligand using standard coupling reagents like EDC or HATU. The chloride group can undergo nucleophilic substitution, for example, with a thiol or amine on an E3 ligase ligand. This dual functionality makes it a versatile building block for PROTAC synthesis.
|
| Molecular Formula |
C10H23CL2NO2
|
|---|---|
| Molecular Weight |
260.20
|
| Exact Mass |
259.11
|
| CAS # |
1035373-85-3
|
| Related CAS # |
NH2-PEG2-C6-Cl;744203-60-9
|
| PubChem CID |
89239696
|
| Appearance |
White to yellow solid powder
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
15
|
| Complexity |
104
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
ClCCCCCCOCCOCCN.Cl
|
| InChi Key |
KRGPBUVQAULFOQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H22ClNO2.ClH/c11-5-3-1-2-4-7-13-9-10-14-8-6-12;/h1-10,12H2;1H
|
| Chemical Name |
2-[2-(6-chlorohexoxy)ethoxy]ethanamine;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~41.67 mg/mL (~160.15 mM )
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.8432 mL | 19.2160 mL | 38.4320 mL | |
| 5 mM | 0.7686 mL | 3.8432 mL | 7.6864 mL | |
| 10 mM | 0.3843 mL | 1.9216 mL | 3.8432 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
